Teva is an example of a company involved in chemical compounding relevant to domestic pharmaceutical production.

The United States produces practically no generic drugs domestically.

Trip predicts that China will never completely cut off the supply of rare earths to the United States.

Trip believes the government's investment in Intel should have been rejected in favor of a competitor like Texas Instruments acquiring or absorbing the assets.

The U.S. is 90% reliant on India for its supply of pharmaceutical precursors and generic drugs.

The U.S. President has issued an executive order to promote domestic pharmaceutical production, which includes creating a list of key precursor chemicals.

Recent high-level diplomatic talks between the U.S. and China did not address rare earth supply chains in depth, focusing instead on agricultural products like soybeans and meat.

India is 100% reliant on China for its supply of pharmaceutical precursors.

The current U.S. administration's industrial policy involves taking equity positions in companies it significantly invests in, rather than only providing grants.

The United States possesses 95% of the rare earth raw materials it needs within the contiguous 48 states.

The United States can become 100% self-reliant in the manufacturing and processing of critical minerals.

Reshoring all manufacturing to the United States is not realistic because the domestic supply chains for many industries, such as textiles, do not exist.

The high cost of labor is not the primary bottleneck for reshoring manufacturing to the U.S. due to the potential of automation.

The U.S. is effectively 100% reliant on China for pharmaceutical precursors due to India's dependence on Chinese supply.

Government incentives for domestic pharmaceutical production will target privately-held chemical compounding companies, not large pharmaceutical firms like Johnson & Johnson, Merck, or Bristol-Myers S...

Trip predicts the U.S. government will issue new incentives, including grants, for domestic pharmaceutical precursor manufacturing in the near future.

The United States lacks the domestic mid-supply chain processing capacity for rare earth materials.

Capital markets currently lack a strong appetite for funding domestic "last-mile" manufacturing, a change from the environment during the Trump administration.